Trial Profile
A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Cerepetide (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors Cend Therapeutics
- 06 Jul 2022 Results published in the Cend Therapeutics Media Release.
- 06 Jul 2022 Results published in the Caladrius Biosciences Media Release.
- 05 Jul 2022 According to a Caladrius Biosciences media release, results from this trial were published in The Lancet Gastroenterology and Hepatology.